Strattera is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera® by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. .

Strattera - Pharmacology:

The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.

Strattera mini report

Strattera NDA
NDA - A product marketed under an approved New Drug Application
Strattera CAPSULE
Strattera KIT
Strattera global name
Atomoxetine hydrochloride
Strattera global name
Strattera global name
Start - Stop data
Start - Stop data
not occurred

Strattera for patients

Patients should read Information for Patients before starting therapy with STRATTERA and when the prescription is renewed.

Patients initiating STRATTERA should be cautioned that liver dysfunction may develop rarely. Patients should be instructed to contact their physician immediately should they develop pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained "flu-like" symptoms.

Patients should be instructed to call their doctor as soon as possible should they notice an increase in aggression or hostility.

Patients should consult a physician if they are taking or plan to take any prescription or over-the-counter medicines, dietary supplements, or herbal remedies.

Patients should consult a physician if they are nursing, pregnant, or thinking of becoming pregnant while taking STRATTERA.

Patients may take STRATTERA with or without food.

If patients miss a dose, they should take it as soon as possible, but should not take more than the prescribed total daily amount of STRATTERA in any 24-hour period.

Patients should use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine.

Strattera Interactions

Drug-Drug Interactions

Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.

CYP2D6 inhibitors - Strattera is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs. Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine. In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.

In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.

Pressor agents - Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents.

Manufacturers name:

  • Eli Lilly and Company
  • Physicians Total Care, Inc
  • Lake Erie Medical DBA Quality Care Products LLC
  • TYA Pharmaceuticals
  • Carilion Materials Management
  • Cardinal Health

Generic name, Overdose, Half Life Strattera, Food Interactions, Chemical, etc..

Strattera see also FDA report Saw Palmetto

General health

Chemical structure:
N O H H H H H H H H H H H H H H H H H H H H H C17H21NO 2D chemical structure C17H21NO SVG | 2D structure Atomoxetine | Diphenhydramine | chemical names, chemical properties, classification C17H21NO